COSCIENS Biopharma Inc. (TSX:CSCI)
Canada · Delayed Price · Currency is CAD | Market Cap | 8.18M +6.1% |
| Revenue (ttm) | 10.28M -21.8% |
| Net Income | -14.20M |
| EPS | -4.49 |
| Shares Out | 3.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131 |
| Average Volume | 1,687 |
| Open | 2.590 |
| Previous Close | 2.570 |
| Day's Range | 2.590 - 2.590 |
| 52-Week Range | 1.100 - 6.000 |
| Beta | 1.88 |
| RSI | 50.63 |
| Earnings Date | May 12, 2026 |
About COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important bi... [Read more]
Financial Performance
In 2025, COSCIENS Biopharma's revenue was $7.50 million, a decrease of -21.79% compared to the previous year's $9.59 million. Losses were -$10.36 million, -32.34% less than in 2024.
Financial numbers in USD Financial StatementsNews
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
TORONTO, ONTARIO, April 20, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced today that it has filed a Rule 13e-3 Transaction Stateme...
COSCIENS Comments on Unusual Market Activity
TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activit...
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, pla...
COSCIENS Provides Strategic Update
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to ...
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagn...
COSCIENS Biopharma Inc. Announces Leadership Change
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmace...
COSCIENS Biopharma Inc (USA) trading resumes
17:40 EDT COSCIENS Biopharma (CSCI)Inc (USA) trading resumes
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq , while retaining the Company's listing on the TSX
COSCIENS Biopharma Inc (USA) trading halted, news pending
17:15 EDT COSCIENS Biopharma (CSCI)Inc (USA) trading halted, news pending
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversifie...
Cosciens Biopharma announces receipt of Goodwood intended director nominations
Cosciens Biopharma (CSCI) confirmed that its board of directors has received a letter from Goodwood Fund and Puccetti Funds Management regarding six director nominations for the company’s upcoming ann...
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversifie...
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; C...
Cosciens Biopharma appoints Biehn as CEO
COSCIENS Biopharma (CSCI)announced the appointment of Anna Biehn as Chief Executive Officer, CEO, effective May 5, 2025. Biehn is a global general management and marketing executive with over 25 years
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operat...
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a divers...
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diver...
Cosciens Biopharma announces possible delay in filing 2024-end documents
COSCIENS Biopharma (CSCI)”announced that there is a potential for delay in the filing of: (a) its annual financial statements as of December 31, 2024 and 2023 and for the years
Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides
COSCIENS Biopharma (CSCI)announced initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed for potential applications in managing conditions related ...
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
TORONTO, ONTARIO, March 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a divers...
Cosciens Biopharma provides update, reiterates pipeline prioritization
COSCIENS Biopharma (CSCI)provided a corporate update and reiterated its pipeline prioritization. The company said, “Pharmaceuticals: Avenanthramides Tablets in Development as an Anti-Inflammatory: The...
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness
Cosciens Biopharma reports Q3 revenue $1.9M vs $2M last year
“We have conducted a thorough evaluation and prioritization of our combined pipeline of products and programs. This evaluation focused on prioritizing programs and products in the nutraceutical and co...
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- C...
Cosciens Biopharma director Carolyn Egbert resigns
COSCIENS Biopharma announced the resignation of Carolyn Egbert from the Board of Directors, effective immediately. “We are extremely grateful to Carolyn for her twelve years of dedicated service to th...